AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Worldwide Hepatitis Therapeutics Markets, 2016-2019 & 2026 - ResearchAndMarkets.com

November 25, 2019

DUBLIN--(BUSINESS WIRE)--Nov 25, 2019--

The “Hepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026” report has been added to ResearchAndMarkets.com’s offering.

This report analyzes the current and future scenario of the global hepatitis therapeutics market. Increase in the prevalence of viral hepatitis, promising hepatitis drug pipeline, and favorable government support are the major drivers of the global market.

The global hepatitis therapeutics market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to segments based on disease type, drug class, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section.

Additionally, the section comprises company profiles with product portfolio to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by region, and market share analysis, by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global hepatitis therapeutics market.

Key Segments

The global hepatitis therapeutics market has been segmented based on disease type, drug class, distribution channel, and region.

In terms of disease type, the global market has been segmented into hepatitis A, hepatitis B, hepatitis C, and others. Based on drug class, the global hepatitis therapeutics market has been categorized into nucleotide analog reverse transcriptase inhibitor, NS5A inhibitor, multi- class combination, nucleotide analog NS5B polymerase inhibitor, interferon & ribavirin, and others. Based on distribution channel, the global market has been divided into hospital pharmacies, retail pharmacies, and others. The market value and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Regional Outlook

The global hepatitis therapeutics market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). The Market Value and forecast for each of these regions and countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Key Topics Covered

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hepatitis Therapeutics Market

4. Market Overview

4.1. Introduction

4.1.1. Industry Evolution/Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Hepatitis Therapeutics Market Analysis and Forecasts, 2016-2026

4.4.1. Market Revenue Projections (US$ Mn)

4.5. Porter’s Five Force Analysis

5. Market Outlook

5.1.Pipeline Analysis

5.2.New Product Launch, Approvals & Patent Expiry

5.3.Regulatory Scenario

6. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Disease Type

6.1. Introduction & Definition

6.2. Market Value Forecast, by Disease Type, 2016-2026

6.2.1. Hepatitis A

6.2.2. Hepatitis B

6.2.3. Hepatitis C

6.2.4. Others

6.3. Market Attractiveness, by Disease Type

7. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Drug Class

7.1. Introduction & Definition

7.2. Market Value Forecast, by Drug Class, 2016-2026

7.2.1. Nucleotide Analog Reverse Transcriptase Inhibitor

7.2.2. NS5A Inhibitor

7.2.3. Multi Class Combination

7.2.4. Nucleotide Analog NS5B Polymerase Inhibitor

7.2.5. Interferon & Ribavirin

7.2.6. Others

7.3. Market Attractiveness, by Drug Class

8. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Distribution Channel

8.1. Introduction & Definition

8.2. Market Value Forecast, by Distribution Channel, 2016-2026

8.2.1. Hospital Pharmacies

8.2.2. Retail Pharmacies

8.2.3. Online Pharmacies

8.4. Market Attractiveness, by Distribution Channel

9. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Region

9.1. Market Value Forecast, by Region

9.1.1. North America

9.1.2. Europe

9.1.3. Asia-Pacific

9.1.4. Latin America

9.1.5. Middle East & Africa

9.2. Market Attractiveness, by Country/Region

10. North America Hepatitis Therapeutics Market Analysis and Forecast

11. Europe Hepatitis Therapeutics Market Analysis and Forecast

12. Asia-Pacific Hepatitis Therapeutics Market Analysis and Forecast

13. Latin America Hepatitis Therapeutics Market Analysis and Forecast

14. Middle East & Africa Hepatitis Therapeutics Market Analysis and Forecast

15. Competition Landscape

15.1. Market Share Analysis, by Company (2017)

15.2. Company Profiles

15.2.1. Gilead Sciences Inc.

15.2.2. F. Hoffmann-La Roche Ltd.

15.2.3. Bristol Myers Squibb

15.2.4. Merck & Co. Inc.

15.2.5. AbbVie Inc.

15.2.6. NATCO Pharma Limited

15.2.7. Zydus Cadila

15.2.8. Hetero Healthcare Limited

15.2.9. LAURUS Labs

15.2.10. Cipla Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ptr76q

View source version on businesswire.com:https://www.businesswire.com/news/home/20191125005698/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: INFECTIOUS DISEASES PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/25/2019 01:07 PM/DISC: 11/25/2019 01:07 PM

http://www.businesswire.com/news/home/20191125005698/en